Mickael Guedj
Overview
Explore the profile of Mickael Guedj including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
2378
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boudjeniba C, Soret P, Trutschel D, Hamon A, Baloche V, Chassagnol B, et al.
Clin Immunol
. 2024 May;
264:110241.
PMID: 38735508
Primary Sjögren disease (pSD) is an autoimmune disease characterized by lymphoid infiltration of exocrine glands leading to dryness of the mucosal surfaces and by the production of autoantibodies. The pathophysiology...
2.
Da Silva J, Bienassis C, Schmitt P, Berjaud C, Guedj M, Paris S
J Exp Clin Cancer Res
. 2024 Jan;
43(1):11.
PMID: 38173001
Purpose: Radiotherapy-activated NBTXR3 (NBTXR3 + RT) has demonstrated superior efficacy in cancer cell destruction and tumor growth control, compared to radiotherapy (RT), in preclinical and clinical settings. Previous studies highlighted...
3.
Baudier C, Fougerousse F, Asselbergs F, Guedj M, Komajda M, Kotecha D, et al.
Front Cardiovasc Med
. 2023 Nov;
10:1148931.
PMID: 37920183
Background: The effects of α and ß adrenergic receptor modulation on the risk of developing heart failure (HF) remains uncertain due to a lack of randomized controlled trials. This study...
4.
Moingeon P, Chenel M, Rousseau C, Voisin E, Guedj M
Drug Discov Today
. 2023 May;
28(7):103605.
PMID: 37146963
Computational models are being explored to simulate in silico the efficacy and safety of drug candidates and medical devices. Disease models that are based on patients' profiling data are being...
5.
Imbert O, Chimits D, Guedj M, Lorieau F, Bernard K, Lalande A, et al.
Osteoarthr Cartil Open
. 2022 Dec;
3(3):100188.
PMID: 36474822
Objectives: Selection of patients with KL radiographic grade 2 and 3 is widely used in clinical trials, but this approach could have some limitations. The purpose of this study performed...
6.
Nabirotchkin S, Bouaziz J, Glibert F, Mandel J, Foucquier J, Hajj R, et al.
J Alzheimers Dis
. 2022 Jul;
88(4):1585-1603.
PMID: 35811522
Background: Human diseases are multi-factorial biological phenomena resulting from perturbations of numerous functional networks. The complex nature of human diseases explains frequently observed marginal or transitory efficacy of mono-therapeutic interventions....
7.
Guedj M, Swindle J, Hamon A, Hubert S, Desvaux E, Laplume J, et al.
Expert Opin Drug Discov
. 2022 Jul;
17(8):815-824.
PMID: 35786124
Introduction: As a mid-size international pharmaceutical company, we initiated 4 years ago the launch of a dedicated high-throughput computing platform supporting drug discovery. The platform named ' was built up...
8.
Laigle L, Le Dantec C, Soret P, Desvaux E, Hubert S, Foulquier N, et al.
Med Sci (Paris)
. 2022 Feb;
38(2):148-151.
PMID: 35179468
No abstract available.
9.
Desvaux E, Aussy A, Hubert S, Keime-Guibert F, Blesius A, Soret P, et al.
Expert Rev Clin Immunol
. 2021 Nov;
18(1):47-56.
PMID: 34842494
Introduction: The complex pathophysiology of autoimmune diseases (AIDs) is being progressively deciphered, providing evidence for a multiplicity of pro-inflammatory pathways underlying heterogeneous clinical phenotypes and disease evolution. Areas Covered: Treatment...
10.
Moingeon P, Kuenemann M, Guedj M
Drug Discov Today
. 2021 Sep;
27(1):215-222.
PMID: 34555509
Artificial Intelligence (AI) relies upon a convergence of technologies with further synergies with life science technologies to capture the value of massive multi-modal data in the form of predictive models...